Thomas Andersson

Corporate Officer/Principal at KDVENTURES AB

74 year

Health Technology

Finance

Consumer Services

Profile

Thomas B. Andersson is currently a Director at Skogsmöllan AB, Kongsberg Beam Technology AS, and Investment Manager at Karolinska Development AB. He was previously the Chief Executive Officer at SpectraCure AB, Annexin Pharmaceuticals AB, and Lund University Bioscience AB from 2007 to 2012.
He was also the Chairman at ProNoxis AB and Director at DermaGen AB. Dr. Andersson holds a graduate and doctorate degree from the University of Lund.

Thomas Andersson active positions

Companies	Position	Start
KDVENTURES AB	Corporate Officer/Principal	-
Kongsberg Beam Technology AS Kongsberg Beam Technology AS Packaged SoftwareTechnology Services Develops an AI-powered radiation therapy software	Director/Board Member	-
Skogsmöllan AB Skogsmöllan AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical preparation services	Director/Board Member	-

All active positions of Thomas Andersson

Former positions of Thomas Andersson

Companies	Position	End
ISOFOL MEDICAL AB	Chief Executive Officer	21/06/2023
Lund University Bioscience AB Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions.	Chief Executive Officer	31/12/2012
ANNEXIN PHARMACEUTICALS AB	Chief Executive Officer	-
SPECTRACURE AB	Chief Executive Officer	-
ProNoxis AB ProNoxis AB Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs to treat chronic inflammation	Chairman	-

See the detail of Thomas Andersson's experience

Training of Thomas Andersson

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Thomas Andersson's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	10
University of Lund University of Lund Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
DermaGen AB DermaGen AB Pharmaceuticals: MajorHealth Technology Develops therapeutic peptides	Health Technology
SpectraCure AB SpectraCure AB Electronic Equipment/InstrumentsElectronic Technology Develops and provides equipment for cancer treatment	Electronic Technology
Lund University Bioscience AB Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions.	Finance
ProNoxis AB ProNoxis AB Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs to treat chronic inflammation	Health Technology
Isofol Medical AB Isofol Medical AB Pharmaceuticals: MajorHealth Technology Provides novel folate-based pharmaceutical products	Health Technology
Karolinska Development AB Karolinska Development AB Financial ConglomeratesFinance Operates as a life sciences investment company	Finance
Annexin Pharmaceuticals AB Annexin Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures drugs for cardiovascular diseases	Health Technology
Skogsmöllan AB Skogsmöllan AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical preparation services	Health Technology
Kongsberg Beam Technology AS Kongsberg Beam Technology AS Packaged SoftwareTechnology Services Develops an AI-powered radiation therapy software	Technology Services